ONCY (Oncolytics Biotech) Shareholder Yield % : -13.99% (As of Mar. 2026)


ONCY Oncolytics Biotech Inc ONCY
32 GF Score
Price $0.88
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech Shareholder Yield %?

Oncolytics Biotech ONCY -2.10% 32 Shareholder Yield % is -13.99% as of Mar. 2026. GuruFocus rates ONCY with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,295 Biotechnology companies, Oncolytics Biotech ranks worse than 73.36% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Oncolytics Biotech's Shareholder Yield % was -13.99%.


Oncolytics Biotech  (NAS:ONCY) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Oncolytics Biotech Shareholder Yield % Related Terms


Oncolytics Biotech Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Oncolytics Biotech's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech Shareholder Yield % Chart

Oncolytics Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.04 -9.10 -23.72 -7.40 -12.28

Oncolytics Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.41 -14.40 -9.43 -12.28 -15.23

ONCY vs VRCA, ENGN, ALDX: Shareholder Yield % Comparison

For the Biotechnology subindustry, Oncolytics Biotech's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Shareholder Yield % falls into.


ONCY
32GF Score
Oncolytics Biotech Inc ONCY
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech Shareholder Yield % Calculation

Oncolytics Biotech's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-15.42 %+0.19 %
=-15.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -13.99% mean?
Oncolytics Biotech (ONCY) has a Shareholder Yield % of -13.99% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Oncolytics Biotech and its competitors. According to the industry distribution chart, Oncolytics Biotech ranks #950 out of 1295 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Oncolytics Biotech's Shareholder Yield % too high?
Oncolytics Biotech's current Shareholder Yield % is -13.99%. Based on the distribution chart, Oncolytics Biotech ranks #950 out of 1295 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncolytics Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's Shareholder Yield % compare to VRCA and ENGN?
According to the Biotechnology industry distribution chart, Oncolytics Biotech ranks #950 out of 1295 companies for Shareholder Yield %. This places Oncolytics Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Oncolytics Biotech and its competitors. Oncolytics Biotech's current Shareholder Yield % is -13.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current Shareholder Yield % of -13.99%. The current Shareholder Yield % is -13.99%. Oncolytics Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current Shareholder Yield % is -13.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
32GF Score

Get the complete analysis for ONCY

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.88
Price